Hypomethylating agents as preferred therapy for higher-risk CMML patients
- fwaberger
- 15. März 2023
- 1 Min. Lesezeit

A research team lead by CCS member Lisa Pleyer (image) and CCS director Richard Greil published data of a retrospective cohort study in The Lancet Haematology. The data suggest hypomethylating agents as the preferred therapy for patients with higher-risk chronic myelomonocytic leukaemia and those with myeloproliferative CMML.
Comments